1.	Phase III Randomized Study of Immunotherapy with an Allogeneic Melanoma Vaccine plus Interferon Alfa vs Interferon Alfa Alone in Patients with Metastatic Malignant Melanoma (Summary Last Modified 04/2000). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CORIXA-2885-14, RIR-2885-14, YALE-HIC-8666, NCI-V96-0883, NCT00002767
2.	Phase III Multicenter, Randomized, Controlled Study of THERATOPE Vaccine in Women With Metastatic Breast Cancer (Summary Last Modified 05/2001) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BIOMIRA-STn-BR-104, NCI-V98-1489, NCT00003638
3.	Phase III Randomized Trial of Adjuvant Immunotherapy with an Allogeneic Melanoma Vaccine for Patients with Intermediate-Thickness, Node-Negative Malignant Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-9035
4.	Phase III Randomized Study of Melacine (Melanoma Cell Lysate Vaccine) vs Chemotherapy with DTIC/CDDP/BCNU/TMX in Patients with Disseminated Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 16 and over Sponsor: Protocol IDs: RIR-91CO28-CC, NCI-V92-0019, NCI-V92-0102
5.	Phase I/II Study of Photodynamic Therapy With Verteporfin and Detox-B Adjuvant in Patients With Stage III or IV Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: QLT-VFI-PDV-01, QLT-PHO-VFI-PDV-01, NCT00007969
6.	Phase II Randomized, Double-Blind Study of 3 Doses of Sialyl Tn-KLH Therapeutic Vaccine with Detox B Adjuvant as Active-Specific Immunotherapy for Colorectal Cancer (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: UNMC-04094, NCI-V94-0589
7.	Phase II Pilot Study of Vaccination with the Ganglioside GM2 Covalently Attached to Keyhole Limpet Hemocyanin plus the Immunological Adjuvant Detox in Patients with Completely Resected Stage III/IV Malignant Melanoma Phase: Phase II Type: Treatment Status: Completed Age: any age Sponsor: Protocol IDs: MSKCC-91012, NCI-V91-0043
8.	Phase II Pilot Adjuvant Study of Vaccination with Sialyl Tn Antigen Covalenty Attached to KLH plus Detox in Patients with High-Risk Resected Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: any age Sponsor: Protocol IDs: MSKCC-91095, NCI-V91-0167
9.	Phase I Pilot Study of Adjuvant Vaccine Therapy With Tumor-Specific Mutated ras Peptides in Patients With Colorectal, Pancreatic, Lung, Breast, or Prostate Cancer (Summary Last Modified 05/2002) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-94-C-0096D, NCI-T93-0152N, T93-0152, NCT00019006
10.	Phase I Study of IL-2/CTX and Autologous Tumor Cell Vaccines in the Treatment of Metastatic Renal Carcinoma and Melanoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: URCC-3788M, NCI-T88-0151D, T88-0151
11.	Phase I Study of Adjuvant IL-1A Immunotherapy with an Allogeneic Colon Cancer Vaccine for Dukes' D Colon or Rectal Cancer (Summary Last Modified 06/97) Phase: Phase I Type: Treatment Status: Completed Age: 21 to 100 Sponsor: NCI Protocol IDs: URCC-4290M, NCI-T91-0094D, T91-0094